Patents Assigned to Sarantis Pty Ltd
  • Component of bromelain
    Patent number: 9663777
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: May 30, 2017
    Assignee: Sarantis Pty Ltd
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • COMPONENT OF BROMELAIN
    Publication number: 20110027259
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Application
    Filed: October 12, 2010
    Publication date: February 3, 2011
    Applicant: SARANTIS PTY LTD
    Inventors: Tracey Lehanne MYNOTT, Christian ENGWERDA, Keith PEEK
  • Component of bromelain
    Patent number: 7833963
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 16, 2010
    Assignee: Sarantis Pty Ltd
    Inventors: Tracey L. Mynott, Christian Engwerda, Keith Peek